4.8 Article

False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases

Journal

FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.666114

Keywords

SARS-CoV-2; autoimmunity; autoantibodies; diagnostics; rheumatoid arthritis; systemic lupus erythematosus; multiple sclerosis; rheumatoid factor

Categories

Funding

  1. Dr. Margaretha Nilsson's Foundation for Medical Research, Vinnova [2020-02865]
  2. PCORI [Patient-Centered Outcomes Research Institute] [MS-1511-33196]
  3. Swedish Research Council
  4. King Gustav V:s 80-year foundation
  5. EU/EFPIA IMI project RTCure [777357]
  6. Professor Nanna Svartz Foundation
  7. Gothenburg Medical Society [GLS-889421]
  8. Western Gotaland county council [ALFGBG-926621]
  9. University of Gothenburg [ALFGBG-926621]
  10. Aina (Ann) Wallstroms och Mary-Ann Sjobloms Foundation for Medical Research

Ask authors/readers for more resources

Commercial serological assays for SARS-CoV-2 have poor specificity in patients with chronic inflammatory diseases, leading to a high risk of false positive results, especially among rheumatoid arthritis patients with rheumatoid factor. Therefore, the possibility of false positivity should be considered when interpreting the results of these tests.
Patients with chronic inflammatory diseases are often treated with immunosuppressants and therefore are of particular concern during the SARS-CoV-2 pandemic. Serological tests will improve our understanding of the infection and immunity in this population, unless they tests give false positive results. The aim of this study was to evaluate the specificity of SARS-Cov-2 serological assays using samples from patients with chronic inflammatory diseases collected prior to April 2019, thus defined as negative. Samples from patients with multiple sclerosis (MS, n=10), rheumatoid arthritis (RA, n=47) with or without rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibodies (anti-CCP2) and systemic lupus erythematosus (SLE, n=10) with or without RF, were analyzed for SARS-CoV-2 antibodies using 17 commercially available lateral flow assays (LFA), two ELISA kits and one in-house developed IgG multiplex bead-based assay. Six LFA and the in-house validated IgG assay correctly produced negative results for all samples. However, the majority of assays (n=13), gave false positive signal for samples from patients with RA and SLE. This was most notable in samples from RF positive RA patients. No false positive samples were detected in any assay using samples from patients with MS. Poor specificity of commercial serological assays could possibly be, at least partly, due to interfering antibodies in samples from patients with chronic inflammatory diseases. For these patients, the risk of false positivity should be considered when interpreting results of the SARS-CoV-2 serological assays.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available